Posted by Michael Wonder on 31 Jan 2024
Ezharmia supplemental new drug application submitted in Japan for patients with peripheral T-cell lymphoma
31 January 2024 - Submission for second indication of Sakigake designated Ezharmia based on VALENTINE-PTCL01 results in patients with relapsed or refractory peripheral T-cell lymphoma.
Daiichi Sankyo has submitted a supplemental new drug application to Japan’s Ministry of Health, Labour and Welfare for Ezharmia (valemetostat tosylate), a first in class dual inhibitor of EZH1 and EZH2, for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma.
